This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Community Pharmacies Remove Pharmaceuticals Remove Research Related Topics
Pharmacy Packaging Licensing Vaccine Drugs Licensing Pharmaceutical Companies Hospitals Production More Related Topics >
article thumbnail

Buprenorphine now replaces methadone as the most common medicine for opioid dependence’: 10-year trends in opioid agonist treatment medicines in Australia

National Drug & Alcohol Research Centre Blog

DECEMBER 4, 2023

In Australia, both methadone and buprenorphine have been subsidised by the Pharmaceutical Benefit Scheme (PBS) for the treatment of opioid dependence (termed ‘opioid agonist treatment’ or OAT) for several decades. The use of opioid agonist treatment increased in non-community pharmacy settings from early 2020.

Treatment 133
Treatment Community Pharmacies Pharmacy International 133
article thumbnail

DrugBank adds ASHP data to knowledgebase, improving user experience and data reliability

DrugBank

NOVEMBER 7, 2023

Together with DrugBank’s complementary products, this integration is expected to improve consumer safety, provide users with a stronger understanding of trends across categories and the research landscape, and enhance analytic capabilities.

Pharmacy 86
Pharmacy Community Pharmacies Packaging Pharmaceutical Companies 86
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024